Remove Computational Chemistry Remove Pharmaceuticals Remove Small Molecule
article thumbnail

Lead Pharma enters into a Research Collaboration and License Agreement with Roche to Develop Oral Small Molecules for Immune Mediated Diseases

The Pharma Data

R&D collaboration building on Lead Pharma’s expertise in the discovery, design and optimization of small molecule treatments. Our rigorous target selection process, translational screening cascade, and smart medicinal chemistry have been essential to bring this project to this stage. About Lead Pharma.

article thumbnail

Sygnature Discovery and Daewoong Pharma announce research collaboration

Sygnature Discovery

Sygnature Discovery is pleased to have entered into a research collaboration agreement with the global healthcare group Daewoong Pharmaceutical to accelerate the discovery of a novel small molecule to target autoimmune disease.

article thumbnail

The Data-Driven Future of Drug Development

DrugBank

By harnessing the vast amounts of data generated throughout the development pipeline, pharmaceutical companies can accelerate the discovery of novel therapies, optimize clinical trial design, enhance drug safety monitoring, and deliver personalized medicine, ultimately improving patient outcomes and transforming the future of healthcare.

article thumbnail

Target-directed cancer: protein-ligand interactions  

Drug Target Review

The mission of the CCDD is to discover novel small-molecule therapeutics for the treatment of cancer and progress them to hypothesis testing phase 1 clinical trials. For example, in the screening stage of a project we are trying to find initial starting points for optimisation by our medicinal and computational chemistry colleagues.

article thumbnail

Accelerating Innovation, Deepening Integration | Viva Biotech Online Investor Day Review

The Pharma Data

Since its establishment, Viva Biotech has been providing comprehensive new drug R&D services to nearly 500 world’s top pharmaceutical and biotech companies based on Viva’s excellence in structure-based drug discovery. Dr. Xueheng Cheng, CTO of Viva Biotech, introduced the ASMS technology platform.

article thumbnail

The Book of Nimbus

LifeSciVC

The premise at the time was that putting computational chemistry in the primary position for new molecule ideation would upend the drug discovery paradigm. set up a “virtual project team,” leverage Schrödinger scientists to lead computational chemistry, and do all the wet work at CROs. It did just that.